Early Study of the Cephea Mitral Valve System for Treating Symptomatic Mitral Valve Disease Using Transcatheter Therapy

What this Trial Is About

Researchers are evaluating the Cephea Mitral Valve System for treating symptomatic patients with mitral valve disease, including mitral regurgitation, mitral stenosis, and mixed mitral valve disease. This study focuses on patients for whom transcatheter therapy is considered more suitable than open heart surgery. The study aims to understand the preliminary safety and effectiveness of this device in such patients. Participants receive the Cephea Mitral Valve System through a transcatheter mitral valve replacement procedure. This is a single-group interventional study where all participants receive the investigational device. The treatment is delivered without comparison to other treatments or placebo. The study is designed to observe outcomes primarily 30 days after the implant. During the study, participants will be monitored closely to evaluate safety and effectiveness endpoints 30 days post-implant. Assessments will include medical evaluations and imaging according to the American Society of Echocardiography criteria. The study will continue follow-up until the primary completion date in December 2026, with overall completion expected by March 2031. Participants can expect regular visits for monitoring and data collection throughout the study period.

Cephea Early Feasibility Study